Free Trial
LON:NCYT

Novacyt 4/30/2026 Earnings Report

Novacyt logo
GBX 78 +31.30 (+67.02%)
As of 09:59 AM Eastern

Novacyt EPS Results

Actual EPS
-GBX 33
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novacyt Revenue Results

Actual Revenue
$20.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Novacyt Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Novacyt Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Novacyt makes Australian acquisition to accelerate global growth
See More Novacyt Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novacyt? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novacyt and other key companies, straight to your email.

About Novacyt

Novacyt (LON:NCYT) is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental. The Company is divided into three business segments: Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments Research Use Only Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV"). For more information, please refer to the website: www.novacyt.com

View Novacyt Profile